After Lobbying Push, Drugmaker Resubmits Women's Sex Pill

The makers of a twice-rejected pill designed to boost female libido are resubmitting their drug to federal health regulators, following a recent lobbying blitz by politicians, women's groups and consumer advocates aimed at pushing it onto the market.

Sprout Pharmaceuticals said Tuesday it is refiling its application for the drug, flibanserin, adding new information requested by the Food and Drug Administration about how the pill affects driving ability. FDA scientists requested that data after their most recent rejection of the drug, in part, due to results showing nearly 10 percent of women in company trials reported sleepiness as a side effect. The company studied women's driving ability the morning after taking flibanserin compared with women taking placebo and a common sleeping pill.

More